Insights Into Differentiated Thyroid Cancer (DTC) 2024

Perspectives on ​the management of radioactive iodine (RAI)-refractory or -ineligible metastatic DTC and second-line systemic therapy

Southeast – April 29, 2024
Purchase Report

Faculty Chair

Marcia Brose, MD, PhD

Sidney Kimmel Cancer Center, Philadelphia, PA, USA

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • Management of RAI-Refractory or -Ineligible Metastatic DTC
  • Second-Line Systemic Therapy

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and in-depth moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.